Short answer: The only option here with an FDA approval is tirzepatide (Zepbound), for moderate to severe obstructive sleep apnea in adults with obesity: in SURMOUNT-OSA, breathing events fell by 25 to 29 per hour vs about 5 on placebo. DSIP rests on a few small studies from 1987 and 1992 that disagree. Growth hormone secretagogue data are tiny. Testosterone may make sleep apnea worse.
| Compound | Best evidence | What it shows |
|---|---|---|
| Tirzepatide (Zepbound) | FDA-approved for this | Approved for moderate to severe obstructive sleep apnea in adults with obesity. Breathing events per hour fell 25.3 vs 5.3 (no CPAP) and 29.3 vs 5.5 (on CPAP) over 52 weeks. |
| DSIP | Small or early human studies | A 1987 study in 14 people with insomnia reported better sleep; a 1992 double-blind study in 16 found weak effects and judged it unlikely to help much. |
| MK-677 (ibutamoren) | Small or early human studies | In 14 adults it lengthened deep sleep and REM sleep. FDA lists ibutamoren in 503A Category 2 (significant safety risks). |
| Ipamorelin, CJC-1295 | No published studies found | We found no published human study of either on sleep. Small studies of natural GHRH given into a vein do not transfer to these products. |
| Testosterone | Approved for a different use | Approved for hypogonadism, not sleep. The Xyosted label warns it may worsen sleep apnea, especially with obesity. |
"Animal or lab studies only" means no published human trial for this goal that we could find. Results in rats or cells often do not carry over to people. Compounds that are not FDA-approved have no tested label for dose, purity or safety.
Obstructive sleep apnea (OSA) is when the airway keeps closing during sleep. Severity is measured with the apnea-hypopnea index (AHI): breathing pauses or shallow breaths per hour.
SURMOUNT-OSA was two 52-week trials in adults with moderate to severe OSA and obesity. One enrolled people not using a CPAP machine, the other people on CPAP. Average AHI at the start was about 50 events per hour.
| Trial | AHI change, Zepbound | AHI change, placebo | Weight change, Zepbound vs placebo |
|---|---|---|---|
| Not using CPAP | -25.3 events/hour | -5.3 events/hour | -17.7% vs -1.6% |
| Using CPAP | -29.3 events/hour | -5.5 events/hour | -19.6% vs -2.3% |
The label approves Zepbound for this use with a reduced-calorie diet and more physical activity. It carries a boxed warning about thyroid C-cell tumors seen in rats. Side effects in the trials were mostly digestive. More on the brand is on the Zepbound page and the tirzepatide guide.
The human data on DSIP (delta sleep-inducing peptide) are old and small. A 1987 study gave DSIP for 7 nights to 14 middle-aged people with chronic insomnia and reported better sleep and daytime alertness. A 1992 double-blind study gave it into a vein to 16 people with chronic insomnia: sleep efficiency was a little higher, but the authors said the effects were weak, partly due to chance changes in the placebo group, and that DSIP was not likely to be of major benefit. We found no modern trial.
Growth hormone and deep sleep are linked. In 1997, natural GHRH given into a vein reduced night-time waking in 13 older adults, but much less than it does in young people. MK-677, an oral growth hormone secretagogue (a compound that makes the pituitary release growth hormone), was tested in 8 young and 6 older adults: in young adults the high dose raised the deepest sleep stage by about 50% and REM sleep by more than 20%. These are tiny, short studies. FDA now lists ibutamoren (MK-677) in Category 2 of its 503A bulk list, for significant safety risks.
For ipamorelin, CJC-1295 and similar injectable peptides, we found no published human study measuring sleep. Claims that they "improve deep sleep" are extrapolated from the studies above.
The Xyosted (testosterone enanthate) label says testosterone may potentiate (worsen) sleep apnea in some people, especially those with obesity or chronic lung disease. The Endocrine Society 2018 guideline advises against starting testosterone in men with untreated severe obstructive sleep apnea.
If you are on TRT and start snoring more, wake up gasping, or feel sleepy all day, tell your clinician. A sleep study is the way to check. See low testosterone for the other label warnings.
Diagnosis and prescribing decisions belong with a licensed clinician who can examine you and order labs.
Terms on this page: GLP-1 receptor agonist · GIP (glucose-dependent insulinotropic polypeptide) · Growth hormone secretagogue